Immune dynamics during blinatumomab therapy in B-cell acute lymphoblastic leukemia

Blinatumomab, a CD19×CD3 bispecific T-cell engager, has become an important component of therapy for B-cell acute lymphoblastic leukemia (B-ALL) across relapsed/refractory, measurable residual disease, consolidation, and selected frontline settings. Its activity depends on functional endogenous T cells and therefore provides a clinically relevant model for studying treatment-associated immune dynamics. Following treatment initiation, circulating T cells undergo rapid redistribution and activation, followed by recovery and expansion of effector and memory populations. In parallel, profound CD19-positive B-cell depletion produces a slower and heterogeneous disturbance of humoral immunity, while transient cytokine release is concentrated predominantly in the early phase of the first treatment cycle. Sustained immune engagement may also be accompanied by inhibitory checkpoint signaling and exhaustion-associated T-cell dysfunction in a subset of patients. Beyond peripheral blood, the bone marrow niche and anatomical compartmentalization may modify the interaction between effector T cells and leukemic targets, although direct evidence linking specific microenvironmental components to clinical blinatumomab resistance remains limited. Resistance and relapse are multifactorial and include reduced or lost CD19 expression, lineage plasticity, inadequate T-cell fitness, treatment-associated T-cell dysfunction, and extramedullary escape. This review synthesizes current evidence on the temporal and compartment-specific immune changes associated with blinatumomab therapy and discusses their implications for response, toxicity, resistance, immune recovery, and future biomarker-guided treatment strategies.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-11-21
DOI
https://doi.org/10.1007/s10238-026-02377-z
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune dynamics during blinatumomab therapy in B-cell acute lymphoblastic leukemia

胡群, A G Liu, Jiale Liu, Yijie Cai
Clinical and Experimental Medicine
Acute Lymphoblastic Leukemia research
article

Immune dynamics during blinatumomab therapy in B-cell acute lymphoblastic leukemia

胡群, A G Liu, Jiale Liu, Yijie Cai
article en

Abstract

Blinatumomab, a CD19×CD3 bispecific T-cell engager, has become an important component of therapy for B-cell acute lymphoblastic leukemia (B-ALL) across relapsed/refractory, measurable residual disease, consolidation, and selected frontline settings. Its activity depends on functional endogenous T cells and therefore provides a clinically relevant model for studying treatment-associated immune dynamics. Following treatment initiation, circulating T cells undergo rapid redistribution and activation, followed by recovery and expansion of effector and memory populations. In parallel, profound CD19-positive B-cell depletion produces a slower and heterogeneous disturbance of humoral immunity, while transient cytokine release is concentrated predominantly in the early phase of the first treatment cycle. Sustained immune engagement may also be accompanied by inhibitory checkpoint signaling and exhaustion-associated T-cell dysfunction in a subset of patients. Beyond peripheral blood, the bone marrow niche and anatomical compartmentalization may modify the interaction between effector T cells and leukemic targets, although direct evidence linking specific microenvironmental components to clinical blinatumomab resistance remains limited. Resistance and relapse are multifactorial and include reduced or lost CD19 expression, lineage plasticity, inadequate T-cell fitness, treatment-associated T-cell dysfunction, and extramedullary escape. This review synthesizes current evidence on the temporal and compartment-specific immune changes associated with blinatumomab therapy and discusses their implications for response, toxicity, resistance, immune recovery, and future biomarker-guided treatment strategies.

Clinical and Experimental Medicine
Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Immune dynamics during blinatumomab therapy in B-cell acute lymphoblastic leukemia — 胡群, A G Liu, et al. · Clinical and Experimental Medicine (2026) | TGRS Research Map | TGRS